Merrimack Pharmaceuticals

OverviewSuggest Edit

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

TypePublic
Founded2000
HQCambridge, MA, US
Websitemerrimack.com
Employee Ratings3

Latest Updates

Employees (est.) (Feb 2019)27(-62%)
Revenue (FY, 2016)$144.3 M(+62%)
Share Price (Jan 2021)$7.6
Cybersecurity ratingCMore

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, MA, US (HQ)
1 Kendall Square
Show all (1)

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Revenue

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.
USD

Net income (Q3, 2020)

(1.0m)

EBIT (Q3, 2020)

(1.0m)

Market capitalization (20-Jan-2021)

101.6m

Closing stock price (20-Jan-2021)

7.6

Cash (30-Sept-2020)

15.8m
Merrimack Pharmaceuticals's current market capitalization is $101.6 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

48.9m47.8m102.8m89.3m144.3m

Revenue growth, %

115%(13%)62%

Cost of goods sold

46.0k6.9m

Gross profit

89.2m137.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

11.3m12.1m11.3m14.7m18.5m6.9m13.0m27.8m28.0m14.8m36.6m16.4m21.3m33.7m28.1m

Cost of goods sold

711.0k1.9m1.0m

Gross profit

20.6m31.8m27.1m

Gross profit Margin, %

97%94%96%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

37.7m65.1m35.7m185.6m21.5m93.4m20.1m16.6m

Accounts Receivable

9.3m5.9m3.3m6.5m17.5m100.0k

Prepaid Expenses

9.0m5.5m4.7m5.5m1.4m4.2m2.1m

Inventories

3.7m14.6m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

30.6m32.0m27.9m28.4m30.9m105.5m66.9m77.8m100.3m28.8m33.7m56.4m48.2m21.5m36.5m17.2m135.5m107.2m34.3m22.5m49.8m36.5m36.9m20.9m18.0m15.7m15.8m

Accounts Receivable

6.0m6.9m6.1m9.8m14.5m8.8m12.2m6.6m2.6m4.2m1.8m2.1m15.6m19.3m22.2m43.0k43.0k190.0k

Prepaid Expenses

6.5m6.6m11.3m10.2m9.2m8.9m2.5m4.4m5.8m3.2m5.4m6.4m4.5m4.6m4.1m2.3m5.9m8.0m844.0k1.7m1.8m4.6m2.1m1.5m1.9m3.6m2.9m

Inventories

8.1m12.3m14.8m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(91.3m)(130.7m)(83.6m)(147.8m)(153.5m)470.9m(40.5m)(17.3m)

Depreciation and Amortization

3.7m2.6m3.2m4.3m6.2m5.2m4.1m2.2m

Inventories

(3.7m)(9.7m)

Accounts Payable

7.0m13.3m(646.0k)13.6m(3.9m)(9.3m)(3.8m)(12.1m)
USDQ1, 2012

Financial Leverage

-0.2 x
Show all financial metrics

Merrimack Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Merrimack Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Merrimack Pharmaceuticals Online and Social Media Presence

Embed Graph

Merrimack Pharmaceuticals News and Updates

Merrimack Pharmaceuticals Announces Changes to Board of Directors

Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective Immediately.read more

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....

Merrimack Pharmaceuticals Blogs

Merrimack Reports Third Quarter 2020 Financial Results

Merrimack Reports Third Quarter 2020 Financial Results Content Import Thu, 11/05/2020 - 08:20 Merrimack Reports Third Quarter 2020 Financial Results November 5, 2020 This release is a backfill from a News Wire Earnings CAMBRIDGE,…

Merrimack Reports Second Quarter 2020 Financial Results

Merrimack Reports Second Quarter 2020 Financial Results Content Import Fri, 08/07/2020 - 08:20 Merrimack Reports Second Quarter 2020 Financial Results August 7, 2020 This release is a backfill from a News Wire Earnings CAMBRIDGE,…

Merrimack Reports First Quarter 2020 Financial Results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020 . “We are pleased to report that we have significantly reduced our operating

Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan Content Import Tue, 12/03/2019 - 09:15 Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan December 3, 2019 This release is a backfill from a News Wire …

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend Content Import Tue, 12/03/2019 - 08:45 Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend December 3, 2019 This …
Show more

Merrimack Pharmaceuticals Frequently Asked Questions

  • When was Merrimack Pharmaceuticals founded?

    Merrimack Pharmaceuticals was founded in 2000.

  • Who are Merrimack Pharmaceuticals key executives?

    Merrimack Pharmaceuticals's key executives are Richard Peters.

  • How many employees does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 27 employees.

  • Who are Merrimack Pharmaceuticals competitors?

    Competitors of Merrimack Pharmaceuticals include Enochian BioSciences, Mirati Therapeutics and Del Mar Pharmaceuticals.

  • Where is Merrimack Pharmaceuticals headquarters?

    Merrimack Pharmaceuticals headquarters is located at 1 Kendall Square, Cambridge.

  • Where are Merrimack Pharmaceuticals offices?

    Merrimack Pharmaceuticals has an office in Cambridge.

  • How many offices does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 1 office.